1 Eaden JA, Abrams KR, and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526-535, 2001.
2 Eaden JA and Mayberry JF: Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 51 Suppl 5: V10-12, 2002.
3 Hata K, Watanabe T, Kazama S, Suzuki K, Shinozaki M, Yokoyama T, Matsuda K, Muto T, and Nagawa H: Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br J Cancer 89: 1232-1236, 2003.
4 Choi CH, Rutter MD, Askari A, Lee GH, Warusavitarne J, Moorghen M, Thomas-Gibson S, Saunders BP, Graham TA, and Hart AL: Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview. Am J Gastroenterol 110: 1022-1034, 2015.
5 Kishikawa J, Hata K, Kazama S, Anzai H, Shinagawa T, Murono K, Kaneko M, Sasaki K, Yasuda K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Nozawa H, Ishihara S, Morikawa T, Fukayama M, and Watanabe T: Results of a 36-year surveillance program for ulcerative colitis-associated neoplasia in the Japanese population. Dig Endosc 30: 236-244, 2018.
6 Ekbom A, Helmick C, Zack M, and Adami HO: Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228-1233, 1990.
7 Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, and Oldenburg B: Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 19: 789-799, 2013.
8 Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., and Kinzler KW: Cancer genome landscapes. Science (New York, NY) 339: 1546-1558, 2013.
9 Itzkowitz SH and Harpaz N: Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126: 1634-1648, 2004.
10 Ullman TA and Itzkowitz SH: Intestinal inflammation and cancer. Gastroenterology 140: 1807-1816, 2011.
11 Scarpa M, Castagliuolo I, Castoro C, Pozza A, Scarpa M, Kotsafti A, and Angriman I: Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis. World J Gastroenterol 20: 6774-6785, 2014.
12 Beaugerie L and Itzkowitz SH: Cancers complicating inflammatory bowel disease. N Engl J Med 372: 1441-1452, 2015.
13 Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, and Burmer GC: Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107: 369-378, 1994.
14 Risques RA, Lai LA, Himmetoglu C, Ebaee A, Li L, Feng Z, Bronner MP, Al-Lahham B, Kowdley KV, Lindor KD, Rabinovitch PS, and Brentnall TA: Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer research 71: 1669-1679, 2011.
15 Galandiuk S, Rodriguez-Justo M, Jeffery R, Nicholson AM, Cheng Y, Oukrif D, Elia G, Leedham SJ, McDonald SA, Wright NA, and Graham TA: Field cancerization in the intestinal epithelium of patients with Crohn's ileocolitis. Gastroenterology 142: 855-864.e858, 2012.
16 Robles AI, Traverso G, Zhang M, Roberts NJ, Khan MA, Joseph C, Lauwers GY, Selaru FM, Popoli M, Pittman ME, Ke X, Hruban RH, Meltzer SJ, Kinzler KW, Vogelstein B, Harris CC, and Papadopoulos N: Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. Gastroenterology 150: 931-943, 2016.
17 Shinagawa T, Hata K, and Watanabe T: Colitis-associated cancer in inflammatory bowel disease and effective endoscopic surveillance programs. Nippon Rinsho 75: 471-476, 2017.
18 Issa JP, Ahuja N, Toyota M, Bronner MP, and Brentnall TA: Accelerated age-related CpG island methylation in ulcerative colitis. Cancer research 61: 3573-3577, 2001.
19 Fujii S, Tominaga K, Kitajima K, Takeda J, Kusaka T, Fujita M, Ichikawa K, Tomita S, Ohkura Y, Ono Y, Imura J, Chiba T, and Fujimori T: Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. Gut 54: 1287-1292, 2005.
20 Pekow J, Meckel K, Dougherty U, Huang Y, Chen X, Almoghrabi A, Mustafi R, Ayaloglu-Butun F, Deng Z, Haider HI, Hart J, Rubin DT, Kwon JH, and Bissonnette M: miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD. Clinical cancer research : an official journal of the American Association for Cancer Research 23: 5281-5291, 2017.
21 Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC, and et al.: Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Human pathology 14: 931-968, 1983.
22 Rubin DT, Rothe JA, Hetzel JT, Cohen RD, and Hanauer SB: Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 65: 998-1004, 2007.
23 Hata K, Kishikawa J, Anzai H, Shinagawa T, Kazama S, Ishii H, Nozawa H, Kawai K, Kiyomatsu T, Tanaka J, Tanaka T, Nishikawa T, Otani K, Yasuda K, Yamaguchi H, Ishihara S, Sunami E, Kitayama J, and Watanabe T: Surveillance colonoscopy for colitis-associated dysplasia and cancer in ulcerative colitis patients. Dig Endosc 28: 260-265, 2016.
24 Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, and Soetikno R: SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology 148: 639-651.e628, 2015.
25 Watanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo SE, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, and Hibi T: Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. Gastroenterology 151: 1122-1130, 2016.
26 Matsumoto T, Nakamura S, Jo Y, Yao T, and Iida M: Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. Am J Gastroenterol 98: 1827-1833, 2003.
27 Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, Chapman M, Itzkowitz S, Steinlauf AF, Abreu MT, Ullman TA, Aisenberg J, and Mayer L: Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol 103: 2342-2349, 2008.
28 Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, Nafe B,Jung M, Galle PR, and Neurath MF: Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124: 880-888, 2003.
29 Hata K, Watanabe T, Motoi T, and Nagawa H: Pitfalls of pit pattern diagnosis in ulcerative colitis-associated dysplasia. Gastroenterology 126: 374-376, 2004.
30 厚生労働科学研究費補助金 難治性疾患等政策研究事業 「難治性炎症性腸管障害に関する調査研究」(鈴木班): 一目でわかる IBD 炎症性腸疾患を診察されている先生方へ. 2015.
31 厚生労働科学研究費補助金 難治性疾患等政策研究事業 「難治性炎症性腸管障害に関する調査研究」(鈴木班): 潰瘍性大腸炎・クローン病 診断基準・治療指針. 2018.
32 Kornbluth A and Sachar DB: Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 105: 501-523; quiz 524, 2010.
33 Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, and Bloom S: Guidelines for the management of inflammatory bowel disease in adults. Gut 60: 571-607, 2011.
34 Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollon F, Hauser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, and Lindsay JO: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. Journal of Crohn's & colitis 7: 1-33, 2013.
35 Shergill AK and Farraye FA: Toward a consensus on endoscopic surveillance of patients with colonic inflammatory bowel disease. Gastrointestinal endoscopy clinics of North America 24: 469-481, 2014.
36 Itzkowitz S: Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. J Clin Gastroenterol 36: S70-74; discussion S94-76, 2003.
37 Watanabe T, Kobunai T, Toda E, Kanazawa T, Kazama Y, Tanaka J, Tanaka T, Yamamoto Y, Hata K, Kojima T, Yokoyama T, Konishi T, Okayama Y, Sugimoto Y, Oka T, Sasaki S, Ajioka Y, Muto T, and Nagawa H: Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray. Clinical cancer research : an official journal of the American Association for Cancer Research 13: 415-420, 2007.
38 Watanabe T, Kobunai T, Yamamoto Y, Ikeuchi H, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T, Yokoyama T, Konishi T, Eshima K, Ajioka Y, Hibi T, Watanabe M, Muto T, and Nagawa H: Predicting ulcerative colitis-associated colorectal cancer using reverse-transcription polymerase chain reaction analysis. Clin Colorectal Cancer 10: 134-141, 2011.
39 Watanabe T, Kobunai T, Ikeuchi H, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T, Yokoyama T, Konishi T, Eshima K, Ajioka Y, Hibi T, Watanabe M, Muto T, and Nagawa H: RUNX3 copy number predicts the development of UC-associated colorectal cancer. Int J Oncol 38: 201-207, 2011.
40 Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, and Sugihara K: Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis 17: 802-808, 2011.
41 Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, and Rabinovitch PS: DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103: 1611-1620, 1992.
42 Shinozaki M, Kobayashi K, Kunisaki R, Hisamatsu T, Naganuma M, Takahashi KI, Iwao Y, Suzuki Y, Watanabe M, Itabashi M, Torii A, Takazoe M, and Sugita A: Surveillance for dysplasia in patients with ulcerative colitis: Discrepancy between guidelines and practice. Dig Endosc 29: 584-593, 2017.
43 Hata K, Watanabe T, Shinozaki M, Kojima T, and Nagawa H: To dye or not to dye? That is beyond question! Optimising surveillance colonoscopy is indispensable for detecting dysplasia in ulcerative colitis. Gut 53: 1722, 2004.
44 Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, and Talbot IC: Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 53: 256-260, 2004.
45 Sada M, Igarashi M, Yoshizawa S, Kobayashi K, Katsumata T, Saigenji K, Otani Y, Okayasu I, and Mitomi H: Dye spraying and magnifying endoscopy for dysplasia and cancer surveillance in ulcerative colitis. Dis Colon Rectum 47: 1816-1823, 2004.
46 Hurlstone DP, Sanders DS, Lobo AJ, McAlindon ME, and Cross SS: Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy 37: 1186-1192, 2005.
47 Toyoshima O, Hata K, Yoshida S, and Arita M: New-generation chromoendoscopy may increase confidence in the DISCARD2 study. Gut 2017.
48 Kudo S, Tamura S, Nakajima T, Yamano H, Kusaka H, and Watanabe H: Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc 44: 8-14, 1996.
49 Tanaka S, Kaltenbach T, Chayama K, and Soetikno R: High-magnification colonoscopy (with videos). Gastrointest Endosc 64: 604-613, 2006.
50 Carballal S, Maisterra S, Lopez-Serrano A, Gimeno-Garcia AZ, Vera MI, Marin-Garbriel JC, Diaz-Tasende J, Marquez L, Alvarez MA, Hernandez L, De Castro L, Gordillo J, Puig I, Vega P, Bustamante-Balen M, Acevedo J, Penas B, Lopez-Ceron M, Ricart E, Cuatrecasas M, Jimeno M, and Pellise M: Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. Gut 67: 70-78, 2018.
51 Bisschops R, Bessissow T, Dekker E, East JE, Para-Blanco A, Ragunath K, Bhandari P, Rutter M, Schoon E, Wilson A, John JM, Van Steen K, Baert F, and Ferrante M: Pit pattern analysis with high-definition chromoendoscopy and narrow-band imaging for optical diagnosis of dysplasia in patients with ulcerative colitis. Gastrointest Endosc 86: 1100-1106.e1101, 2017.
52 Kudo S, Hirota S, Nakajima T, Hosobe S, Kusaka H, Kobayashi T, Himori M, and Yagyuu A: Colorectal tumours and pit pattern. Journal of clinical pathology 47: 880-885, 1994.
53 Sugimoto S, Naganuma M, Iwao Y, Matsuoka K, Shimoda M, Mikami S, Mizuno S, Nakazato Y, Nanki K, Inoue N, Ogata H, and Kanai T: Endoscopic morphologic features of ulcerative colitis-associated dysplasia classified according to the SCENIC consensus statement. Gastrointest Endosc 85: 639-646.e632, 2017.
54 Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV, Jr., Pena AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, and Warren BF: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 19 Suppl A: 5a-36a, 2005.
55 Schroeder KW, Tremaine WJ, and Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317: 1625-1629, 1987.
56 Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, and Woodhouse CR: Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59: 666-689, 2010.
57 Participants. PW: The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 58: S3-43, 2003.
58 Shinagawa T, Hata K, Morikawa T, Takiyama H, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Nozawa H, Ishihara S, Nakamura H, Fukayama M, and Watanabe T: Protrusion on the Depressed Surface of Non-polypoid T1 Colorectal Cancer Is Associated with Venous Invasion. Anticancer research 38: 993-1002, 2018.
59 Ishigooka S, Nomoto M, Obinata N, Oishi Y, Sato Y, Nakatsu S, Suzuki M, Ikeda Y, Maehata T, Kimura T, Watanabe Y, Nakajima T, Yamano HO, Yasuda H, and Itoh F: Evaluation of magnifying colonoscopy in the diagnosis of serrated polyps. World J Gastroenterol 18: 4308-4316, 2012.
60 Kanda Y: Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone marrow transplantation 48: 452-458, 2013.
61 McHugh ML: Interrater reliability: the kappa statistic. Biochemia medica 22: 276-282, 2012.
62 Kudo S, Rubio CA, Teixeira CR, Kashida H, and Kogure E: Pit pattern in colorectal neoplasia: endoscopic magnifying view. Endoscopy 33: 367-373, 2001.
63 Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, and Kaplan GG: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet (London, England) 390: 2769-2778, 2018.
64 Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, and Ito Y: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124, 2002.
65 Li QL, Kim HR, Kim WJ, Choi JK, Lee YH, Kim HM, Li LS, Kim H, Chang J, Ito Y, Youl Lee K, and Bae SC: Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochemical and biophysical research communications 314: 223-228, 2004.
66 Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG, and Ito Y: RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer research 65: 7743-7750, 2005.
67 Ito K, Inoue KI, Bae SC, and Ito Y: Runx3 expression in gastrointestinal tract epithelium: resolving the controversy. Oncogene 28: 1379-1384, 2009.
68 Weersma RK, Zhou L, Nolte IM, van der Steege G, van Dullemen HM, Oosterom E, Bok L, Peppelenbosch MP, Faber KN, Kleibeuker JH, and Dijkstra G: Runt-related transcription factor 3 is associated with ulcerative colitis and shows epistasis with solute carrier family 22, members 4 and 5. Inflamm Bowel Dis 14: 1615-1622, 2008.
69 Kang KA, Kim KC, Bae SC, and Hyun JW: Oxidative stress induces proliferation of colorectal cancer cells by inhibiting RUNX3 and activating the Akt signaling pathway. Int J Oncol 43: 1511-1516, 2013.
70 Emmett RA, Davidson KL, Gould NJ, and Arasaradnam RP: DNA methylation patterns in ulcerative colitis-associated cancer: a systematic review. Epigenomics 9: 1029-1042, 2017.
71 Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, and Sukumar S: RUNX3 Is Frequently Inactivated by Dual Mechanisms of Protein Mislocalization and Promoter Hypermethylation in Breast Cancer. Cancer Research 66: 6512-6520, 2006.
72 Soong R, Shah N, Peh BK, Chong PY, Ng SS, Zeps N, Joseph D, Salto-Tellez M, Iacopetta B, and Ito Y: The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br J Cancer 100: 676-679, 2009.
73 Rasband WS: ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2016.
74 Kim BR, Kang MH, Kim JL, Na YJ, Park SH, Lee SI, Kang S, Joung SY, Lee SY, Lee DH, Min BW, and Oh SC: RUNX3 inhibits the metastasis and angiogenesis of colorectal cancer. Oncology reports 36: 2601-2608, 2016.
75 Li H, Li D, and Meng N: Effects of RUNX3 mediated Notch signaling pathway on biological characteristics of colorectal cancer cells. Int J Oncol 50: 2059-2068, 2017.
76 Milner JJ, Toma C, Yu B, Zhang K, Omilusik K, Phan AT, Wang D, Getzler AJ, Nguyen T, Crotty S, Wang W, Pipkin ME, and Goldrath AW: Runx3 programs CD8(+) T cell residency in non-lymphoid tissues and tumours. Nature 552: 253-257, 2017.
77 Garrity-Park MM, Loftus EV, Jr., Sandborn WJ, Bryant SC, and Smyrk TC: Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol 105: 1610-1619, 2010.
78 Garrity-Park M, Loftus EV, Jr., Sandborn WJ, and Smyrk TC: Myeloperoxidase immunohistochemistry as a measure of disease activity in ulcerative colitis: association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation. Inflamm Bowel Dis 18: 275-283, 2012.
79 Garrity-Park MM, Loftus EV, Jr., Bryant SC, and Smyrk TC: A Biomarker Panel to Detect Synchronous Neoplasm in Non-neoplastic Surveillance Biopsies from Patients with Ulcerative Colitis. Inflamm Bowel Dis 22: 1568-1574, 2016.
80 Suzuki K, Muto T, Masaki T, and Morioka Y: Microspectrophotometric DNA analysis in ulcerative colitis with special reference to its application in diagnosis of carcinoma and dysplasia. Gut 31: 1266-1270, 1990.